Feltl D - Search Results

1

Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks) : an alternative in the treatment of locally advanced head and neck cancer.

Kubes J, Cvek J, Vondracek V, Pala M, Feltl D. Kubes J, et al. Among authors: feltl d. Strahlenther Onkol. 2011 Oct;187(10):651-5. doi: 10.1007/s00066-011-2246-2. Epub 2011 Sep 23. Strahlenther Onkol. 2011. PMID: 21947124

2

Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer.

Cvek J, Knybel L, Skacelikova E, Stransky J, Matousek P, Zelenik K, Res O, Otahal B, Molenda L, Feltl D. Cvek J, et al. Among authors: feltl d. Strahlenther Onkol. 2016 Jan;192(1):40-6. doi: 10.1007/s00066-015-0886-3. Epub 2015 Aug 28. Strahlenther Onkol. 2016. PMID: 26314584

3

Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.

Cvek J, Kubes J, Skacelikova E, Otahal B, Kominek P, Halamka M, Feltl D. Cvek J, et al. Among authors: feltl d. Strahlenther Onkol. 2012 Aug;188(8):666-70. doi: 10.1007/s00066-012-0128-x. Epub 2012 Jun 1. Strahlenther Onkol. 2012. PMID: 22648405 Clinical Trial.

4

The dynamics of plasma transforming growth factor beta 1 (TGF-beta1) level during radiotherapy with or without simultaneous chemotherapy in advanced head and neck cancer.

Feltl D, Zavadova E, Pala M, Hozak P. Feltl D, et al. Oral Oncol. 2005 Feb;41(2):208-13. doi: 10.1016/j.oraloncology.2004.09.005. Oral Oncol. 2005. PMID: 15695123

5

Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer.

Halamka M, Cvek J, Kubes J, Zavadova E, Kominek P, Horacek J, Dusek L, Feltl D. Halamka M, et al. Among authors: feltl d. Oral Oncol. 2011 Aug;47(8):763-7. doi: 10.1016/j.oraloncology.2011.05.009. Epub 2011 Jun 21. Oral Oncol. 2011. PMID: 21696999 Clinical Trial.

6

Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer.

Feltl D, Závadová E, Pála M, Hozák P. Feltl D, et al. Neoplasma. 2005;52(5):393-7. Neoplasma. 2005. PMID: 16151583

7

Is there an intermediate-risk non-seminoma? long-term treatment results from a single center.

Cvek J, Feltl D, Hajek J, Jackaninova J, Ruzickova K, Havranek O, Dvorackova J, Dobes P. Cvek J, et al. Among authors: feltl d. J BUON. 2014 Jul-Sep;19(3):775-9. J BUON. 2014. PMID: 25261666 Free article.

8

Symptomatic osteoradionecrosis of pelvic bones in patients with gynecological malignancies-result of a long-term follow-up.

Feltl D, Vosmik M, Jirásek M, Stáhalová V, Kubes J. Feltl D, et al. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):478-83. doi: 10.1111/j.1525-1438.2006.00540.x. Int J Gynecol Cancer. 2006. PMID: 16681714

9

[HARDROCK project: parametric data collection and analysis of patients with head and neck cancer in the comprehensive cancer centre of Ostrava - role of fractionation and target volume definition in radiotherapy].

Halámka M, Feltl D, Cvek J, Dušek L. Halámka M, et al. Among authors: feltl d. Klin Onkol. 2012;25(4):274-81. Klin Onkol. 2012. PMID: 22920168 Czech.

10

[Intensity Modulated Hyperfractionated Accelerated Radiotherapy to Treat Advanced Head and Neck Cancer - Predictive Factors of Overall Survival].

Cvek J, Knybel L, Stránský J, Matoušek P, Res O, Zeleník K, Otáhal B, Molenda L, Skácelíková E, Stieberová N, Čermáková Z, Feltl D. Cvek J, et al. Among authors: feltl d. Klin Onkol. 2017 Summer;30(4):282-288. doi: 10.14735/amko2017282. Klin Onkol. 2017. PMID: 28832174 Czech.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40 results

Search Page

Filters